Evidence map›Paper›PMID 42164513›Full record

ArticleFrontiers in immunology2026

Immune cells and high-density lipoprotein cholesterol derivative markers mediate the impact of hypertriglyceridemia on hyperuricemia in diabetes mellitus.

Wei Wang, Xiu Ping Qiu, Yang Chen, Xiu Li Guo

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei WangNational Metabolic Management Center, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
Xiu Ping QiuNational Metabolic Management Center, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
Yang ChenNational Metabolic Management Center, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
Xiu Li GuoNational Metabolic Management Center, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As markers of inflammation and oxidative stress, immune cells and high-density lipoprotein cholesterol (HDL-c) derivative markers, such as the monocyte to HDL-c ratio (MHR) and lymphocyte to HDL-c ratio (LHR), have been widely utilized in clinical practice. This study aims to elucidate the roles of MHR and LHR in the impact of hypertriglyceridemia (HTG) on hyperuricemia (HUA) in diabetes mellitus (DM) from a clinical perspective. Methods: The final analysis included 976 individuals with DM. The correlations of MHR and LHR with HTG and HUA were evaluated using the restricted cubic splines (RCS) and binomial logistic regression analysis. Additionally, the mediating role of MHR and LHR in the effect of HTG on HUA was assessed using an adjusted mediation analysis. Results: Participants in the HTG and HUA groups demonstrated significantly elevated MHR and LHR levels (All Conclusion: Both MHR and LHR partially mediate the effect of HTG on HUA, indicating the vital effect of inflammation and oxidative stress in this association.

Indexed as

Cholesterol, HDLDiabetes MellitusHypertriglyceridemiaHyperuricemiaLymphocytesMonocytesAgedBiomarkersFemaleHumansMaleMiddle AgedOxidative StressUric AcidBiomarkersCholesterol, HDLUric Acidhypertriglyceridemiahyperuricemiainflammation and oxidative stresslymphocyte to high-density lipoprotein cholesterol ratiomonocyte to high-density lipoprotein cholesterol ratio

Identifiers

PMID42164513
PMCPMC13183575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.